Mayne Pharma Group Ltd (ASX: MYX) today announced the launch of Tolsura (SUBA -itraconazole) 65mg capsule in the United States.
The company said Tolsura is a new formulation of intraconazole indicated for the treatment of systemic fungal infections.
The serious infections that Mayne Pharma is referring to most commonly occur in vulnerable or immunocompromised patients, such as those with a history of cancer, transplants, HIV/AIDS or chronic rheumatic disorders.
Mayne Pharma has also completed the recruitment and training of a specialised field sales team who are now promoting the benefits of Tolsura to infectious disease physicians.
After receiving US Food and Drug Administration (FDA) approval for Tolsura last month, the company has been quick in launching the product before the end of January.
Mr Scott Richards, Mayne Pharma's CEO, said there may be further promising updates in the future "We look forward to bringing further specialty product innovations to market over the coming years with our pipeline of products under development."
